The consensus among analysts is that Fortress Biotech, Inc. (FBIO) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 6 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.
Fortress Biotech, Inc. (NASDAQ:FBIO) trade information
Wall Street analysts have a consensus price target for the stock at $10.33, which means that the shares’ value could jump 123.11% from the levels at last check today. The projected low price target is $5 while the price target rests at a high of $24. In that case, then, we find that the latest price level in today’s session is +418.36% off the targeted high while a plunge would see the stock lose 7.99% from the levels at last check today.
Fortress Biotech, Inc. (FBIO) estimates and forecasts
Figures show that Fortress Biotech, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +86.61% over the past 6 months, with this year growth rate of 16.92%, compared to 8.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 15.8% and 42.1% for the next quarter. Revenue growth from the last financial year stood is estimated to be +46.8%.
5 analysts offering their estimates for the company have set an average revenue estimate of $13.4 Million for the current quarter. 5 have an estimated revenue figure of $15.13 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $11.29 Million for this quarter, and analysts expect sales will grow by 18.7% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +12.2% over the past 5 years. Earnings growth for 2021 is a modest +11.5% while over the next 5 years, the company’s earnings are expected to increase by 25.5%.
Fortress Biotech, Inc. (NASDAQ:FBIO)’s Major holders
Insiders own 31.39% of the company shares, while shares held by institutions stand at 34.62% with a share float percentage of 50.46%. Investors are also buoyed by the number of investors in a company, with Fortress Biotech, Inc. having a total of 113 institutions that hold shares in the company. The top two institutional holders are Nantahala Capital Management, LLC with over 8.68 Million shares worth more than $27.52 Million. As of December 30, 2020, Nantahala Capital Management, LLC held 9.15% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 4.72 Million shares as of December 30, 2020. The firm’s total holdings are worth over $14.96 Million and represent 4.97% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of December 30, 2020, the former fund manager holds about 2.04% shares in the company for having 1937455 shares of worth $6.14 Million while later fund manager owns 1.54 Million shares of worth $5.42 Million as of March 30, 2021, which makes it owner of about 1.62% of company’s outstanding stock.